Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGairola, Neha-
dc.contributor.authorJoshi, Sonali N-
dc.contributor.authorDhaneshwar, Suneela S-
dc.identifier.issn0975-0967 (Online); 0972-5849 (Print)-
dc.description.abstractRNA interference (RNAi) or gene silencing technology is a phenomenon by which double stranded RNAs elicit degradation of a target mRNA containing homologous sequence. It is essentially a new incarnation of well-established antisense principle. This technology enables the researchers to trigger post-transcriptional gene silencing in vivo. It is a robust method for lowering specific protein levels, compared to traditional techniques such as antisense, ribozymes or microinjection of function-blocking antibodies. RNAi offers a powerful tool for ascribing functions to genes while its application to in vivo models of disease opens up tremendous opportunities to develop a novel generation of oligonucleotide-based drugs, thus offering an enormous potential of being developed as a therapeutic modality.en_US
dc.relation.ispartofseriesInt. Cl.7 A61K31/713; 48/00en_US
dc.sourceIJBT Vol.4(3) [July 2005]en_US
dc.subjectantisense technologyen_US
dc.subjectRNA interference (RNAi)en_US
dc.subjectgene silencingen_US
dc.subjectshort interfering RNAs (siRNA)en_US
dc.titleRNA Interference: A revolution in drug developmenten_US
Appears in Collections:IJBT Vol.04(3) [July 2005]

Files in This Item:
File Description SizeFormat 
IJBT 4(3) 316-322.pdf108.08 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.